A novel endogenous inhibitor for the treatment of diabetic nephropathy

一种治疗糖尿病肾病的新型内源性抑制剂

• 批准号: nhmrc : 1122176
• 负责人: Dr Phillip Kantharidis
• 金额: $ 52.86万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-endogenous-inhibitor-diabetic-nephropathy/946885
• 关键词: novel; endogenous; inhibitor; treatment; diabetic

In various kidney diseases including the most common cause of end stage kidney disease, diabetic nephropathy, identifying the molecular mechanisms responsible for kidney failure are needed to assist in defining new targets and to develop more effective treatments. The proposed studies highlight the potential of a naturally occurring endogenous molecule called Lipoxin, as a modulator of kidney injury which may provide us with a novel approach to tackle the problem of diabetic nephropathy.

在各种肾脏疾病中，包括终末期肾病最常见的原因--糖尿病肾病，需要确定导致肾衰竭的分子机制，以帮助确定新的靶点和开发更有效的治疗方法。拟议的研究强调了一种名为脂氧素的自然产生的内源性分子作为肾脏损伤调节剂的潜力，这可能为我们提供一种新的方法来解决糖尿病肾病问题。